Takić, Marija

Link to this page

Authority KeyName Variants
1f6cbae1-9814-41ea-b2e5-a4fd95944117
  • Takić, Marija (2)
Projects

Author's Bibliography

Influence of Higenamine on Exercise Performance of Recreational Female Athletes: A Randomized Double-Blinded Placebo-Controlled Trial

Rašić, Jelena; Ivanović, Nevena; Anđelković, Marija; Nedeljković, Ivana; Nikolić, Ivan; Stojanović, Sava; Ristić-Medić, Danijela; Takić, Marija; Đorđević, Brižta; Dikić, Nenad

(Frontiers Media S.A., 2021)

TY  - JOUR
AU  - Rašić, Jelena
AU  - Ivanović, Nevena
AU  - Anđelković, Marija
AU  - Nedeljković, Ivana
AU  - Nikolić, Ivan
AU  - Stojanović, Sava
AU  - Ristić-Medić, Danijela
AU  - Takić, Marija
AU  - Đorđević, Brižta
AU  - Dikić, Nenad
PY  - 2021
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/3972
AB  - The aim of this study was to determine the ergogenic effects and the safety profile of a one-component higenamine supplement in female recreational athletes. Twelve recreational female basketball players (age 29–41 years, oxygen consumption (VO2max) > 30 ml⋅kg–1⋅min–1, with training > 5 h wk–1) were randomized either to the higenamine group, or to the placebo group for 3 weeks. In order to determine ergogenic effects and safety profile of higenamine administration, we assessed the following variables before and after 3 weeks of supplementation: anthropometric parameters, resting metabolic rate (RMR), exercise testing variables, serum free fatty acids (FFAs), blood pressure, enzyme activity, urea, lipid profile, and complete blood count. There were no differences between groups in anthropometric parameters, including basal metabolic rate (BMR), RMR and body fat [p = 0.706 (Cohen’s d 0.223), p = 0.169 (Cohen’s d 0.857), and p = 0.223 (Cohen’s d 0.750), respectively], FFAs [0.43 ± 0.03 vs. 0.54 ± 0.23, p = 0.206 (Cohen’s d 0.540)], neither significant differences in cardiopulmonary parameters after the intervention period. Furthermore, all measured outcome variables in the safety assessment were not significant, with values remaining stable during the intervention period for participants in both groups. This is the first study to document the effects and the safety profile of higenamine-based dietary supplements at a specified dose in female recreational athletes. Our data indicate that 21-day of supplementation with 75 mg higenamine would not result in improving cardiopulmonary exercise fitness and weight loss in female recreational athletes. Moreover, supplementation with 75 mg higenamine is safe and well-tolerated in younger recreational female athletes.
PB  - Frontiers Media S.A.
T2  - Frontiers in Psychology
T1  - Influence of Higenamine on Exercise Performance of Recreational Female Athletes: A Randomized Double-Blinded Placebo-Controlled Trial
VL  - 12
DO  - 10.3389/fpsyg.2021.633110
ER  - 
@article{
author = "Rašić, Jelena and Ivanović, Nevena and Anđelković, Marija and Nedeljković, Ivana and Nikolić, Ivan and Stojanović, Sava and Ristić-Medić, Danijela and Takić, Marija and Đorđević, Brižta and Dikić, Nenad",
year = "2021",
abstract = "The aim of this study was to determine the ergogenic effects and the safety profile of a one-component higenamine supplement in female recreational athletes. Twelve recreational female basketball players (age 29–41 years, oxygen consumption (VO2max) > 30 ml⋅kg–1⋅min–1, with training > 5 h wk–1) were randomized either to the higenamine group, or to the placebo group for 3 weeks. In order to determine ergogenic effects and safety profile of higenamine administration, we assessed the following variables before and after 3 weeks of supplementation: anthropometric parameters, resting metabolic rate (RMR), exercise testing variables, serum free fatty acids (FFAs), blood pressure, enzyme activity, urea, lipid profile, and complete blood count. There were no differences between groups in anthropometric parameters, including basal metabolic rate (BMR), RMR and body fat [p = 0.706 (Cohen’s d 0.223), p = 0.169 (Cohen’s d 0.857), and p = 0.223 (Cohen’s d 0.750), respectively], FFAs [0.43 ± 0.03 vs. 0.54 ± 0.23, p = 0.206 (Cohen’s d 0.540)], neither significant differences in cardiopulmonary parameters after the intervention period. Furthermore, all measured outcome variables in the safety assessment were not significant, with values remaining stable during the intervention period for participants in both groups. This is the first study to document the effects and the safety profile of higenamine-based dietary supplements at a specified dose in female recreational athletes. Our data indicate that 21-day of supplementation with 75 mg higenamine would not result in improving cardiopulmonary exercise fitness and weight loss in female recreational athletes. Moreover, supplementation with 75 mg higenamine is safe and well-tolerated in younger recreational female athletes.",
publisher = "Frontiers Media S.A.",
journal = "Frontiers in Psychology",
title = "Influence of Higenamine on Exercise Performance of Recreational Female Athletes: A Randomized Double-Blinded Placebo-Controlled Trial",
volume = "12",
doi = "10.3389/fpsyg.2021.633110"
}
Rašić, J., Ivanović, N., Anđelković, M., Nedeljković, I., Nikolić, I., Stojanović, S., Ristić-Medić, D., Takić, M., Đorđević, B.,& Dikić, N.. (2021). Influence of Higenamine on Exercise Performance of Recreational Female Athletes: A Randomized Double-Blinded Placebo-Controlled Trial. in Frontiers in Psychology
Frontiers Media S.A.., 12.
https://doi.org/10.3389/fpsyg.2021.633110
Rašić J, Ivanović N, Anđelković M, Nedeljković I, Nikolić I, Stojanović S, Ristić-Medić D, Takić M, Đorđević B, Dikić N. Influence of Higenamine on Exercise Performance of Recreational Female Athletes: A Randomized Double-Blinded Placebo-Controlled Trial. in Frontiers in Psychology. 2021;12.
doi:10.3389/fpsyg.2021.633110 .
Rašić, Jelena, Ivanović, Nevena, Anđelković, Marija, Nedeljković, Ivana, Nikolić, Ivan, Stojanović, Sava, Ristić-Medić, Danijela, Takić, Marija, Đorđević, Brižta, Dikić, Nenad, "Influence of Higenamine on Exercise Performance of Recreational Female Athletes: A Randomized Double-Blinded Placebo-Controlled Trial" in Frontiers in Psychology, 12 (2021),
https://doi.org/10.3389/fpsyg.2021.633110 . .
2
6
2
6

Effects of Alpha-Lipoic Acid Supplementation on Plasma Adiponectin Levels and Some Metabolic Risk Factors in Patients with Schizophrenia

Vidović, Bojana; Milovanović, Srđan; Stefanović, Aleksandra; Kotur-Stevuljević, Jelena; Takić, Marija; Debeljak-Martacić, Jasmina; Pantović, Maja; Đorđević, Brižita

(Mary Ann Liebert, Inc, New Rochelle, 2017)

TY  - JOUR
AU  - Vidović, Bojana
AU  - Milovanović, Srđan
AU  - Stefanović, Aleksandra
AU  - Kotur-Stevuljević, Jelena
AU  - Takić, Marija
AU  - Debeljak-Martacić, Jasmina
AU  - Pantović, Maja
AU  - Đorđević, Brižita
PY  - 2017
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/2957
AB  - Adiponectin is an adipocyte-derived plasma protein with insulin-sensitizing and anti-inflammatory properties and is suggested to be a biomarker of metabolic disturbances. The aim of this study was to investigate the effects of alphalipoic acid (ALA) on plasma adiponectin and some metabolic risk factors in patients with schizophrenia. The plasma adipokine levels (adiponectin and leptin), routine biochemical and anthropometric parameters, markers of oxidative stress, and the serum phospholipid fatty acid profile in eighteen schizophrenic patients at baseline, in the middle, and at the end of a 3-month long supplementation period with ALA (500 mg daily) were determined. A significant increase in the plasma adiponectin concentrations, as well as a decrease in fasting glucose and aspartate aminotransferase activity (AST), was found. Baseline AST activity was independently correlated with the adiponectin concentrations. Our data show that ALA can improve plasma adiponectin levels and may play a potential role in the treatment of metabolic risk factor in patients with schizophrenia. Future randomized controlled trials are needed to confirm these preliminary investigations.
PB  - Mary Ann Liebert, Inc, New Rochelle
T2  - Journal of Medicinal Food
T1  - Effects of Alpha-Lipoic Acid Supplementation on Plasma Adiponectin Levels and Some Metabolic Risk Factors in Patients with Schizophrenia
VL  - 20
IS  - 1
SP  - 79
EP  - 85
DO  - 10.1089/jmf.2016.0070
ER  - 
@article{
author = "Vidović, Bojana and Milovanović, Srđan and Stefanović, Aleksandra and Kotur-Stevuljević, Jelena and Takić, Marija and Debeljak-Martacić, Jasmina and Pantović, Maja and Đorđević, Brižita",
year = "2017",
abstract = "Adiponectin is an adipocyte-derived plasma protein with insulin-sensitizing and anti-inflammatory properties and is suggested to be a biomarker of metabolic disturbances. The aim of this study was to investigate the effects of alphalipoic acid (ALA) on plasma adiponectin and some metabolic risk factors in patients with schizophrenia. The plasma adipokine levels (adiponectin and leptin), routine biochemical and anthropometric parameters, markers of oxidative stress, and the serum phospholipid fatty acid profile in eighteen schizophrenic patients at baseline, in the middle, and at the end of a 3-month long supplementation period with ALA (500 mg daily) were determined. A significant increase in the plasma adiponectin concentrations, as well as a decrease in fasting glucose and aspartate aminotransferase activity (AST), was found. Baseline AST activity was independently correlated with the adiponectin concentrations. Our data show that ALA can improve plasma adiponectin levels and may play a potential role in the treatment of metabolic risk factor in patients with schizophrenia. Future randomized controlled trials are needed to confirm these preliminary investigations.",
publisher = "Mary Ann Liebert, Inc, New Rochelle",
journal = "Journal of Medicinal Food",
title = "Effects of Alpha-Lipoic Acid Supplementation on Plasma Adiponectin Levels and Some Metabolic Risk Factors in Patients with Schizophrenia",
volume = "20",
number = "1",
pages = "79-85",
doi = "10.1089/jmf.2016.0070"
}
Vidović, B., Milovanović, S., Stefanović, A., Kotur-Stevuljević, J., Takić, M., Debeljak-Martacić, J., Pantović, M.,& Đorđević, B.. (2017). Effects of Alpha-Lipoic Acid Supplementation on Plasma Adiponectin Levels and Some Metabolic Risk Factors in Patients with Schizophrenia. in Journal of Medicinal Food
Mary Ann Liebert, Inc, New Rochelle., 20(1), 79-85.
https://doi.org/10.1089/jmf.2016.0070
Vidović B, Milovanović S, Stefanović A, Kotur-Stevuljević J, Takić M, Debeljak-Martacić J, Pantović M, Đorđević B. Effects of Alpha-Lipoic Acid Supplementation on Plasma Adiponectin Levels and Some Metabolic Risk Factors in Patients with Schizophrenia. in Journal of Medicinal Food. 2017;20(1):79-85.
doi:10.1089/jmf.2016.0070 .
Vidović, Bojana, Milovanović, Srđan, Stefanović, Aleksandra, Kotur-Stevuljević, Jelena, Takić, Marija, Debeljak-Martacić, Jasmina, Pantović, Maja, Đorđević, Brižita, "Effects of Alpha-Lipoic Acid Supplementation on Plasma Adiponectin Levels and Some Metabolic Risk Factors in Patients with Schizophrenia" in Journal of Medicinal Food, 20, no. 1 (2017):79-85,
https://doi.org/10.1089/jmf.2016.0070 . .
1
19
13
17